Reported 3 months ago
Novavax stock has seen a significant decline after JPMorgan downgraded its rating from Neutral to Underweight. This follows a remarkable 250% surge in the stock price since May, driven by a strategic partnership announcement with Sanofi. Analysts are discussing the implications of this downgrade and the factors influencing the stock's recent performance.
Source: YAHOO